Abstract:Background: Standard insulin infusion sets (IISs) are to be replaced every two-to-three days to avoid complications and diabetic ketosis due to set failure. This pivotal trial evaluated the safety and performance of a new extended-wear infusion set (EIS) when used for seven days by adults with type 1 diabetes (T1D). Method: This single-arm, non-randomized trial enrolled adults (aged 18-80 years) with T1D who used their own MiniMed™ 670G system with insulin lispro or insulin aspart and the EIS for up to seven days, across 12 consecutive wears. Safety endpoints included incidence of serious adverse events (SAEs), serious adverse device effects (SADEs), unanticipated adverse device effects (UADEs), severe hypoglycemia (SevHypo) and severe hyperglycemia (SevHyper), diabetic ketoacidosis (DKA) and skin infection. Effectiveness endpoints included EIS failure due to unexplained hyperglycemia (i.e., suspected occlusion) and overall EIS survival at end of 7-day wear. Exploratory endpoints included change in glycemic outcomes (i.e., A1C, mean glucose and percentage of time at glucose ranges), total daily insulin dose and satisfaction with the EIS. Results: The intention to treat population (n=259, 48% men, 45.0±14.1 years) wore a total of 3,041 EIS devices. No SADEs, UADEs, or DKA events were reported. Overall rates of SAEs, SevHypo, SevHyper and skin infection were 3.8, 2.5, 104.1 and 20.1 events per 100 participant-years. The rate of EIS failure due to unexplained hyperglycemia at end of day 7 was 0.1% (95% C.I., 0.03-0.51%) and 0.4% (95% CI, 0.16-1.00%) for insulin lispro and aspart use, respectively. The overall EIS survival rate was 77.8% (C.I. 76.2%-79.3%) and participants reported greater satisfaction with the EIS compared with standard IISs worn before the study (p<0.001). Conclusions: This investigation demonstrated that the EIS, when worn for up to seven days, was safe and rated with high satisfaction, without adversely affecting glycemic control in adults with T1D.

Development of the Extended Infusion Set and Its Mechanism of Action

994-P: Clinical Study of a New Extended Wear Infusion Set

Advances in Insulin Infusion Set in the New Era of Automated Insulin Delivery: A Systematic Review

The improved survival rate and cost-effectiveness of a 7-day continuous subcutaneous insulin infusion set

Evaluation of Extended Infusion Set Performance in Adults with Type 1 Diabetes: Infusion Set Survival Rate and Glycemic Outcomes from a Pivotal Trial

Longevity of the novel ConvaTec infusion set with Lantern technology

Clinical observation and nursing care on patients with type 2 diabetes applied as continuous subcutaneous insulin infusion

Survival assessment of the extended‐wear insulin infusion set featuring lantern technology in adults with type 1 diabetes by the glucose clamp technique

997-P: Testing a Novel Infusion Set for Extended Wear Duration

Using Insulin Infusion Sets in CSII for Longer Than the Recommended Usage Time Leads to a High Risk for Adverse Events

Tissue Response to Subcutaneous Infusion Catheter

In Vivo Study of the Inflammatory Tissue Response Surrounding a Novel Extended-Wear Kink-Resistant Insulin Infusion Set Prototype Compared With a Commercial Control Over Two Weeks of Wear Time

Combining an Electrochemical Continuous Glucose Sensor With an Insulin Delivery Cannula: A Feasibility Study

A Portable System for Continuous Intravenous Insulin Delivery: Characteristics and Results in Diabetic Patients

Extended use of a new continuous glucose monitoring system with wireless data transmission in children with type 1 diabetes mellitus

Feasibility study of a prototype extended‐wear insulin infusion set in adults with type 1 diabetes

986-P: Assessment of Adhesive Patches for an Extended-Wear Infusion Set

Automated Insulin Delivery with Remote Real-Time Continuous Glucose Monitoring for Hospitalized Patients with Diabetes: A Multicenter, Single-Arm, Feasibility Trial

Long-Term Safety and Efficacy of Programmable Implantable Insulin Delivery Systems

INTEGRATED INSULIN PUMP AND CONTINUOUS GLUCOSE MONITORING TECHNOLOGY IN DIABETES CARE TODAY: A PERSPECTIVE OF REAL-LIFE EXPERIENCE WITH THE MINIMED™ 670G HYBRID CLOSED-LOOP SYSTEM.

Diabetes Technology Update: Use of Insulin Pumps and Continuous Glucose Monitoring in the Hospital